Talis Biomedical Class Action – Kehoe Law Firm, PC Investigation

0

Kehoe Law Firm, PC

Class action on behalf of investors who have acquired TLIS in accordance with and / or traceable to the registration statement and prospectus in connection with the IPO of TLIS

PHILADELPHIA, PA, United States, Jan. 7, 2022 /EINPresswire.com/ – Kehoe Law Firm, PC investigates whether Talis Biomedical Corporation (“Talis” or the “Company”) (NASDAQ: TLIS) has violated federal laws on securities.

TLIS INVESTORS WHO ACQUIRED THEIR SECURITIES IN ACCORDANCE WITH AND / OR TRACEABLE TO THE REGISTRATION STATEMENT AND THE PROSPECTUS ISSUED AS PART OF THE COMPANY’S INITIAL PUBLIC OFFER (“IPO”) IN FEBRUARY 2021 ARE ENCOURAGED TO DISCUSS JOIN THE CLASS ACTION BY CLICKING OR ON “JOIN THE CLASS ACTION”. (https://kehoelawfirm.com/securities-class-action-questionnaire) OR “SECURITIES CLASS ACTION QUESTIONNAIRE” (https://kehoelawfirm.com/securities-class-action-questionnaire).

On January 7, 2021, a class action lawsuit was filed (3: 22-cv-00105) in United States District Court, Northern District of California, on behalf of the persons and entities who purchased or otherwise acquired common stock. of Talis in accordance with and / or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with the Company’s IPO in February 2021.

The registration statement, according to the complaint, was materially false and misleading and failed to indicate (1) that the comparison test in the primary study lacked sufficient sensitivity to support Talis’ EUA request for the Talis test. One COVID-19; (2) as a result, Talis was reasonably likely to experience delays in obtaining regulatory approval for the Talis One COVID-19 test; (3) as a result, the Company’s marketing schedule would be significantly delayed; and (4) as a result of the foregoing, the positive statements of the Talis Defendants regarding the business, operations and prospects of the Company were substantially misleading and / or lacked reasonable basis.

TALIS INVESTORS WITH FINANCIAL LOSSES ARE ALSO ENCOURAGED TO CONTACT JOHN KEHOE, ESQ., (215) 792-6676, EXT. 801, [email protected], [email protected], TO DISCUSS THE TALIS CLASS ACTION INVESTIGATION OR POTENTIAL LEGAL CLAIMS.

Kehoe Law Firm, PC, with offices in New York and Philadelphia, is a multidisciplinary, plaintiff-side law firm dedicated to protecting investors against securities fraud, breach of fiduciary duty and malpractice. Together, the partners of Kehoe Law Firm, PC have acted as a senior advisor or co-senior advisor in cases that have raised more than $ 10 billion on behalf of institutional and individual investors.

This press release may constitute legal advertising.

John Kehoe, Esq.
Kehoe Law Firm, PC
2157926676, EXT. 801
write us here
Visit us on social networks:
Facebook
Twitter
LinkedIn



Source link

Share.

About Author

Comments are closed.